Meet the Visionary Team Behind Psycheceutical


Our mission at Psycheceutical is to develop, improve, and commercialize cutting-edge delivery technologies that can be used across the mental health treatment spectrum while providing safe and effective delivery of psychedelic pharmaceutical medicines.

Meet The Team

FDA Drug Development Veterans

Our team of industry experts has 100+ years of combined experience in psychedelics, biotechnology, and business development across the pharmaceutical industry.

Savvy Technologists and Mental Health Science Experts

Our visionary founders are considered among the top minds in the psychedelic space, embracing the latest technologies to further the advancement of mental health science.

State-of-the-Art Biotech Solutions

Our groundbreaking Janus particle solution and NeuroDirect™ delivery system allow psychedelic compounds to be administered without unwanted side effects and toxicity.


Click to read each team member’s bio
Zappy Zapolin

Zappy Zapolin

Chief Visionary Officer
Dr. Julian E. Bailes

Dr. Julian E. Bailes

Principal Medical Advisor
Kevin Harrington

Kevin Harrington

Strategic Advisor

Chad Harman

Chief Executive Officer

Dr. Anish Tuteja

Chief Science Officer

Michael Hlavsa

Chief Financial Officer
Kaia Roman

Kaia Roman

VP, Strategy & Communications

Advisory Team

Michael Gurin

Board Member
Dr. John Kutzko

Dr. John Kutzko

Formulations Advisor
Dr. Ronald Aung-Din

Dr. Ronald Aung-Din

Clinical Advisor
Dr. Zachary Clayton

Dr. Zachary Clayton

Research Advisor

Dan Yerace

Strategic Adviser

Strategic Partners

Founded by Dr. Anish Dhanarajan, PhD and Francesca Minale, MEng in 2016, Vici is a world-class pharmaceutical product development company working hard to identify unmet pharmaceutical needs that can be solved by drug development through the 505(b)(2) NDA or ANDA pathway.

In pursuit of this goal, Vici operates a rapid, low-cost, high quality prototyping R&D facility capable of GMP operations in Maryland, USA, and is an end-to-end pharmaceutical R&D company capable of taking projects from inception through FDA approval.

Anish Dhanarajan, PhD

Anish Dhanarajan, PhD

Francesca Minale, MEng

Francesca Minale, MEng


A catalyst for developing therapies that improve outcomes, Coeptis accelerates commercialization opportunities by creating valuable partnerships with companies focused on quality, value, and innovation.

The experienced Coeptis team of healthcare professionals seek unique opportunities to improve outcomes for patients.

Dave Mehalick

Co-Founder & CEO

Christine Sheehy

Co-Founder, SVP of Operations, CFO

Gary Conte

SVP of Sales and Marketing